skip to main content

NSCLC Consolidation — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardMedical OncologyNSCLC ConsolidationRACP Adult Medicine

A 65-year-old man with stage IIIA non-small cell lung cancer (unresectable) completes concurrent chemoradiation with carboplatin/paclitaxel. His PD-L1 TPS is 40%. What is the recommended consolidation therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Durvalumab for up to 12 months

The PACIFIC trial demonstrated that consolidation immunotherapy with durvalumab (anti-PD-L1) for up to 12 months following concurrent chemoradiation in unresectable stage III NSCLC significantly improved overall survival and progression-free survival. Durvalumab is PBS-listed in Australia for this indication. Treatment should commence within 42 days of completing chemoradiation.

Reference: Cancer Council Australia – 2021 – Optimal Care Pathway for Lung Cancer; PBS – 2025 – Durvalumab Listing